ASN's Mission

To create a world without kidney diseases, the ASN Alliance for Kidney Health elevates care by educating and informing, driving breakthroughs and innovation, and advocating for policies that create transformative changes in kidney medicine throughout the world.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005


The Latest on X

Kidney Week

Please note that you are viewing an archived section from 2022 and some content may be unavailable. To unlock all content for 2022, please visit the archives.

Abstract: SA-PO318

The Prevalence of Thrombocytopenia in Chronic Hemodialysis Patients Using Low-Molecular-Weight Heparin (Enoxaparin Sodium) vs. Standard Unfractionated Heparin for Hemodialysis Anticoagulation

Session Information

Category: Dialysis

  • 701 Dialysis: Hemodialysis and Frequent Dialysis


  • Sobremisana, James Areja, Armed Forces of the Philippines Medical Center, Diliman, Quezon City, NCR, Philippines
  • Montepio, Rafael, Armed Forces of the Philippines Medical Center, Diliman, Quezon City, NCR, Philippines

Anticoagulation is essential for the prevention of blood clots in the extracorporeal circuit during hemodialysis. For decades, unfractionated heparin has been used for this purpose, however there were noted several disadvantages, hence the search for other anticoagulants with better effects have been studied. One of the effects of anticoagulation during hemodialysis is thrombocytopenia. This study aims to determine the prevalence of thrombocytopenia in chronic kidney disease patients on hemodialysis using unfractionated heparin and using low molecular weight heparin.


This study used a cross-sectional study design of hemodialysis patients comparing the prevalence of thrombocytopenia from the Enoxaparin arm with the Unfractionated Heparin arm of the study. Low molecular weight heparin was given at 0.2cc as bolus 30 minutes to 1 hour prior to hemodialysis. Unfractionated heparin was administered at 50 IU/kg bolus then at 1000 IU per hour. Thrombocytopenia was defined as decrease of 50% from baseline platelet count prior to usage or <150 x 109/L.


The total number of patients recruited that was currently on hemodialysis were 161 patients. A total of 127 patients were included in the study due to exclusion criteria. The Heparin arm (n1=119 patients), and Enoxaparin arm (n2= 42 patients) were included and compared. Overall mean age of the included patients is 48.2 ± 15.2 years. Majority were males and the most common reason for dialysis was Chronic Glomerulonephritis. The age, marital status, cause and reason for HD were homogenous. Among the 127 patients, 22 patients had thrombocytopenia, 16 patients (17.2 %; 95% CI: 10.6 to 25.8) were under the heparin group, while 6 patients (17.6 %; 95% CI: 7.7 to 32.8) were under the enoxaparin group.


It is observed in this study that there is a high prevalence of thrombocytopenia in these study population (17.2-17.6%), compared to the known incidence of hemodialysis-related thrombocytopenia (0.2-12%). Although data is not sufficient to conclude that thrombocytopenia among these patients can be solely attributed to heparin use. Thrombocytopenia occurrence in patients who use unfractionated heparin and low-molecular weight heparin was not statistically significant between the two groups.